Pre-Existing Conditions and GLP-1s: What Your Doctor Will Screen For
Not every condition disqualifies you. Here's what your provider should be evaluating — and why.
GLP-1 medications have a well-established safety profile, but they're not appropriate for everyone. A thorough provider will screen for several conditions before prescribing. Some are absolute contraindications — meaning the medication should not be used. Others require a case-by-case assessment where the benefits and risks are weighed individually.
Here's what a good screening looks like, condition by condition.
This is listed as a contraindication on all GLP-1 receptor agonist labels. If you or a blood relative has been diagnosed with medullary thyroid cancer, GLP-1 medications should not be prescribed. In animal studies, GLP-1 receptor agonists caused thyroid C-cell tumors in rodents. Whether this translates to humans is not definitively established, but the FDA requires a boxed warning on all GLP-1 labels as a precaution. Your doctor should ask about personal and family thyroid cancer history during screening.
MEN2 is a rare genetic condition that predisposes individuals to medullary thyroid carcinoma, among other tumors. For the same reason MTC is contraindicated, MEN2 is an absolute disqualifier. If you have a family history of multiple endocrine tumors, mention this to your provider.
GLP-1 medications may cause fetal harm. The FDA prescribing information for Wegovy states that the medication should be discontinued when pregnancy is recognized. If you are pregnant, planning to become pregnant, or breastfeeding, GLP-1 medications are not appropriate. For oral semaglutide specifically, the absorption enhancer SNAC crosses the placenta in animal studies, and its effects on human fetal development are unknown. Breastfeeding is also not recommended during treatment with oral Wegovy.
If you've had a serious allergic reaction to semaglutide, tirzepatide, or any inactive ingredient in the formulation, the medication should not be used. Symptoms of a serious reaction include swelling of the face, lips, tongue, or throat, difficulty breathing, or severe rash.
GLP-1 receptor agonists carry a warning about acute pancreatitis. If you have a history of pancreatitis, your provider should assess whether the benefits of treatment outweigh the risk. Some providers will prescribe with closer monitoring. If you develop severe, persistent abdominal pain while on a GLP-1, contact your provider immediately — this is a symptom that warrants urgent evaluation.
Rapid weight loss — from any cause — increases the risk of gallstones. GLP-1 medications have been associated with cholelithiasis (gallstones) and cholecystitis (gallbladder inflammation) in clinical trials. If you have a history of gallbladder problems or have had your gallbladder removed, let your provider know. It doesn't necessarily disqualify you, but it affects monitoring.
GLP-1 medications are not directly nephrotoxic, but the GI side effects (nausea, vomiting, diarrhea) can cause dehydration, which may worsen kidney function. Cases of acute kidney injury have been reported, primarily in patients who became significantly dehydrated. If you have chronic kidney disease, your provider should monitor kidney function and ensure adequate hydration guidance.
GLP-1 medications slow gastric emptying — that's part of how they work. If you already have delayed gastric emptying (gastroparesis) or severe GERD, GLP-1s may worsen your symptoms. This doesn't mean treatment is impossible, but it requires careful assessment. Some patients tolerate the medication with slower dose titration.
In patients with type 2 diabetes and existing diabetic retinopathy, rapid improvement in blood sugar control — which GLP-1s can produce — has been associated with temporary worsening of eye disease. If you have diabetic retinopathy, your provider should arrange ophthalmologic monitoring, particularly during the early months of treatment.
The FDA added language about monitoring for suicidal behavior and ideation to GLP-1 labels as a precaution. If you have a history of depression, anxiety, or suicidal thoughts, tell your provider. This doesn't preclude treatment, but it should be part of the monitoring plan. Any significant mood changes while on a GLP-1 should be reported to your provider.
GLP-1 medications significantly suppress appetite, which may be complicated for individuals with a history of restrictive eating disorders. A thoughtful provider will discuss how appetite suppression may interact with disordered eating patterns and may recommend coordinated care with a mental health professional.
What a Good Screening Looks Like
A thorough GLP-1 evaluation should cover all of the above — not just BMI. If your provider's entire screening consists of "What's your height and weight?" and "Are you pregnant?", that's inadequate. The FDA prescribing information lists specific warnings and precautions for a reason.
Expect your provider to ask about thyroid cancer history (personal and family), current medications, pregnancy status, history of pancreatitis, kidney disease, GI conditions, mental health, and eating disorders. If they don't ask, bring it up yourself.